drugset / Trial / NCT02046655

Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI

NCT02046655

Phase 4 Completed 80 enrolled Aristotle University Of Thessaloniki
RandomizedParallel-groupSingle-blindTreatment

Summary

Corifollitropin alfa has been shown to result in significantly more oocytes compared to daily recombinant follicle stimulating hormone (recFSH) (Devroey et al., 2009), probably due to the higher circulating FSH activity during the first days of stimulation. For this reason, the use of corifollitropin alfa might be beneficial in poor responders in whom the number of oocytes retrieved is crucial for success. The purpose of this study is to evaluate the effectiveness of corifollitropin alfa treatment compared to daily recFSH in terms of the number of oocytes retrieved in a defined population of poor responder patients undergoing intracytoplasmic sperm injection (ICSI) using gonadotrophin releasing hormone (GnRH) antagonists.

Timeline

Start
2011-01
Primary completion
2014-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Corifollitropin alfa Protein / enzyme biologic 150 ug Subcutaneous
Comparator Recombinant human follicle stimulating hormone (r-hFSH) Protein / enzyme biologic 450 iu Subcutaneous

Indications